针对癌症患者的染色体不稳定性
Duaa H Al-Rawi1,2,3, Emanuele Lettera1,2, Jun Li1,2
1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nature reviews. Clinical oncology
|July 11, 2024
概括
染色体不稳定 (CIN) 驱动癌症的进展和治疗耐药性. 最近的进展为针对癌症患者的CIN提供了新的治疗策略和生物标志物.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 染色体不稳定 (CIN) 是癌症的一个普遍的标志,在60-80%的人类恶性瘤中存在.
- CIN驱动癌症的关键特征,包括转移,治疗耐药性和免疫逃避.
- 目前针对CIN癌症的治疗策略受到缺乏特定药物和生物标志物的限制.
研究的目的:
- 审查了解CIN的机制和后果的最新进展.
- 要突出转化进展在开发治疗干预措施的CIN驱动的癌症.
- 确定在临床环境中针对CIN的挑战和机会.
主要方法:
- 关于CIN.最近研究的综合文献综述.
- 分析细胞机制和染色体分离错误的临床影响.
- 对CIN新兴治疗策略和生物标志物的评估.
主要成果:
- 对理解CIN在癌症发展和进展中的作用的显著扩展.
- 对CIN阳性瘤的新型治疗标和策略的识别.
- 开发用于评估和量化患者中CIN的新方法.
结论:
- 在CIN研究的进步为治疗染色体不稳定的癌症提供了新的途径.
- 解决目标识别和生物标志物开发方面的挑战对于临床翻译至关重要.
- 准CIN代表了瘤学的一个有前途的前沿.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


